ClinicalTrials.gg
Status unknownNCT03476109PREDICTUMABUpdated Oct 27, 2022

Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

A Phase 4 interventional study of Randomisation to omalizumab and Randomisation to mepolizumab in Severe Asthma, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Status unknown at 13 sites in Belgium. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Phase 4, Interventional, and Treatment

How we know · 2 judgments

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 131 studies in Asthma with a site in Belgium — 10 open to participants now, 17 under way, 4 of them phase 3. Asthma · Belgium.

Planned enrollment
81st of 120
100 · median 218
Started
2019
with 6 others
Phase 4
18 of 131
none open now
Registered
89th of 131
by date

Among the 131 studies in Asthma with a site in Belgium, this one is the 81st largest by planned enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2019, is one of 18 in phase 4, and was the 89th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

10 of the 131 studies in Asthma with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Asthma with a site in Belgium, or all of them as a file.
02

Study summary

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.

Read the detailed description

Title "PREDICTUMAB: Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a multicenter, open, active-controlled, randomized trial in adult patients in Belgium".

Rationale and background New treatments are now available to treat severe refractory asthma, which affects about 3 to 5% of asthma patients. In particular, biological therapies using monoclonal antibodies targeted to immunoglobulin E (IgE) or interleukin (IL)-5 (and in the future other cytokines or growth factors) benefit to certain patients. Identifying those patients who will better benefit from a specific treatment requires the validation of features (clinical traits, biomarkers) that are predictive of the therapeutic outcome. Such predictive strategy is not available to decide whether anti-IgE (omalizumab) or anti-IL-5 (mepolizumab) should be prioritized in patients who are eligible to both therapies. In addition, the comparison of the magnitude of the clinical benefits achieved by these therapies remains unexplored in this population.

Study Design

The study is designed to initially randomly allocate patients from two strata (with or without maintenance oral corticosteroids) to oma- vs mepolizumab. According to the evaluation of response (at 4 or 6 months, respectively), subjects will then be either prolonged (for 12 months, for both therapies) on the same therapy, or switched to the other. For those who were switched, treatment will be prolonged (or not, in dual failers) after 4 or 6 months according to their evaluation of response. Time-points for analysis will be at 4 or 6 months, 10 months (interim analysis) and 18 or 22 months (final, posttreatment analysis).

State-of-the-art

Asthma is one of the most frequent chronic diseases, affecting 5 to 10% of the population worldwide. Omalizumab and mepolizumab represent the approved antibodies that are indicated in allergic and eosinophilic phenotypes of severe asthma respectively. However, if some patients fall into only one phenotypic category based on these criteria, a substantial number of patients are potentially eligible to both therapies. In those patients, no information is available to orientate towards a preferable therapy as the predictive weight of additional phenotypic traits, such as associated nasal polyps or early- versus late onset of disease, remains unknown. In addition, no head-to-head comparison of these therapies is available in this population.

Objectives of the study

Primary objectives To determine clinical features and blood (or sputum) biomarkers able to predict a better response to omalizumab or mepolizumab in severe asthma patients eligible to both therapies.

To determine the magnitude of response, in terms of improvement in symptoms, exacerbation rate and/or lung function, in responders to omalizumab vs mepolizumab.

Secondary objectives To compare the global baseline characteristics (clinical and biological features) of patients responding to omalizumab vs mepolizumab.

Management and reporting of adverse events.

If during the study, an adverse event (AE) (serious or non-serious) is identified as attributed to omalizumab or mepolizumab, this will be documented as appropriate in routine good clinical practice, to the Federal Agency of Medicines and Products of Health (AFMPS) as well as to the Central Ethic Committee.

Confidentiality of data.

The identity and participation of subjects will remain strictly confidential, according to Belgian laws dated 8 Dec 1992 related to the protection of private life and dated 22 Aug 2002 related to patient rights.

Specimens and associated data will be labeled with unique patient identification number.

Data will be anonymized in all files, results and publications related to the study.

The promoter confirms to authorize the regulatory surveillance, examination and controls by competent authorities, by allowing direct access to database/files, and this in full respect of confidentiality.

03

Conditions studied

  • Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: • Signed form (ICF),

  • Age >18+ years at time of signing ICF,
  • Able to comply with the study protocol, in the investigator's judgment,
  • Documented physician-diagnosed asthma ,
  • Patients with severe disease and eligible to omalizumab and mepolizumab, and who have not yet received any of these therapies.

Exclusion Criteria:

  • History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient's ability to participate in the study, in the opinion of the investigator
  • Treatment with any therapy within 6 months or 5 drug half-lives prior to enrolment.
  • Known sensitivity to any of the active substances or their to be administered during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Omalizumab

    Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo). Non responders will be switched to mepolizumab arm.

    Drug: Randomisation to mepolizumab

  • Active comparator
    Mepolizumab

    Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo). Non responders will be switched to omalizumab arm.

    Drug: Randomisation to omalizumab

Interventions

  • DrugRandomisation to omalizumab

    The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.

    Also known as: Active-controlled

  • DrugRandomisation to mepolizumab

    The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.

    Also known as: Active-controlled

This study also gives OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Efficacy on asthma symptoms

    Asthma Control Test: 5 items of score 1 to 5 about symptoms, with result of 20 or above indicates good control; 15 to 19 indicates no good control and below 15 indicates no control at all, and a change of 3 points considered as clinically significant.

    Time frame: Up to 22 months

  2. Efficacy on lung function

    Lung function measured as forced expiratory volume in one sec (FEV1), % predicted value (normal value of 80% predicted or above, and change of 100 mL considered as clinically significant).

    Time frame: Up to 22 months

  3. Efficacy on severe exacerbations

    Number of exacerbation(s) per period of time (corrected per year) requiring systemic corticosteroid treatment for at least 3 days, and/or emergency visit or hospitalization for acute asthma.

    Time frame: Up to 22 months

Secondary outcomes

  1. Predictive factors of therapeutic response

    The putative predictive factors of therapeutic response to omalizumab or mepolizumab which will be assayed are the following: age at onset, year (\> or \< 30yrs); presence of nasal polyps, Y/N; blood eosinophils, n/microliter (\< or \> 300/microl); serum total IgE, units/L; serum periostin, ng/ml. A proteomic analysis will also be carried out on plasma samples.

    Time frame: Baseline features (and according to response at 22 months)

07

Study locations

1 of 13 sites recruiting
  • Universitair Ziekenhuis Brussel
    Brussel, Brussels 1090, Belgium
    Not yet recruiting
    • Shane Hanon, MD · Contact
  • CHU de Charleroi
    Charleroi, Hainaut 6000, Belgium
    Not yet recruiting
    • Rudi Peche, MD · Contact
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6000, Belgium
    Not yet recruiting
    • Pol-Marie Mingeot, MD · Contact
  • Katholieke Universiteit Leuven
    Leuven, Vlaams Brabant 3000, Belgium
    Not yet recruiting
    • Lieven Dupont, MD, PhD · Contact
  • AZ Delta Roeselare
    Roeselare, West-vlaanderen 8800, Belgium
    Not yet recruiting
    • Ulriche Himpe, MD · Contact
  • Cliniques universitaires St-Luc
    Brussels, 1200, Belgium
    Recruiting
  • Centre Hospitalier Universitaire Saint Pierre
    Bruxelles, 1000, Belgium
    Not yet recruiting
    • Vincent Ninane, MD · Contact
  • Brugmann University Hospital
    Bruxelles, 1020, Belgium
    Not yet recruiting
    • Olivier Michel, MD, PhD · Contact
  • Erasme University Hospital
    Bruxelles, 1070, Belgium
    Not yet recruiting
    • Alain Michils, MD · Contact
  • University Hospital, Ghent
    Gent, 9000, Belgium
    Not yet recruiting
    • Guy Brusselle, MD, PhD · Contact
  • University Hospital of Liege
    Liège, 4000, Belgium
    Not yet recruiting
    • Florence Schleich, MD, PhD · Contact
  • CHR Namur
    Namur, 5000, Belgium
    Not yet recruiting
    • Vincent Hers, MD · Contact
  • Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
    Namur, 5530, Belgium
    Not yet recruiting
    • Olivier Vandenplas, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2023, 55 months after the start.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 55 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Mar 23, 2018
StartActual
May 10, 2019
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2024
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03476109
Collaborators
University Hospital, Ghent, University of Liege, CHU de Charleroi, Erasme University Hospital, Centre Hospitalier Universitaire UCLouvain Namur, Universitair Ziekenhuis Brussel, Brugmann University Hospital, Grand Hôpital de Charleroi, AZ Delta, Centre Hospitalier Universitaire Saint Pierre, KU Leuven
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
May 10, 2019
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Oct 27, 2022

Study contacts

Charles Pilette, MD PhD
Contact
charles.pilette@uclouvain.be
003227642866 ext. 2866
Irina KAIDALINA-MAMBOUR, Inf
Contact
irina.kaidalina-mambour@uclouvain.be
003227642813 ext. 2813
Charles Pilette
principal investigator · Cliniques universitaires Saint-Luc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omalizumab

Start the discussion